Update on the management of ulcerative colitis: Treatment and maintenance approaches focused on MMX® mesalamine

Clinical Pharmacology: Advances and Applications

Volumn 4, Issue 1, 2012, Pages 41-50

  Nanda, Kavinderjit ^a   Moss, Alan C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

5 ASA; Inflammatory bowel disease; Mesalamine; Ulcerative colitis

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; 6 MERCAPTOPURINE DERIVATIVE; AMINOSALICYLIC ACID DERIVATIVE; AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; EUDRAGIT; HYDROCORTISONE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PLACEBO; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR INHIBITOR; WARFARIN;

ABDOMINAL PAIN; AREA UNDER THE CURVE; BLOOD DYSCRASIA; COLON POLYP; COLON RESECTION; COLORECTAL CANCER; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG COATING; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPEPSIA; ENCAPSULATION; ENTERITIS; GASTROINTESTINAL SYMPTOM; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; LEUKAPHERESIS; MAINTENANCE THERAPY; MALAISE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEPHROTOXICITY; OLIGOSPERMIA; PANCREATITIS; PATIENT COMPLIANCE; PHARMACODYNAMICS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RECTUM HEMORRHAGE; RELAPSE; REMISSION; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXIC HEPATITIS; ULCERATIVE COLITIS; VOMITING;

EID: 84930474294     PISSN: None     EISSN: 11791438     Source Type: Journal    
DOI: 10.2147/CPAA.S26556     Document Type: Review

References (93)

1. Loftus CG, Loftus Jr EV, Harmsen WS, et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis. 2007;13(3): 254-261.
2. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365(18): 1713-1725.
3. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105(3):501-523.
4. Ricart E, Panaccione R, Loftus Jr EV, et al. Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study. Inflamm Bowel Dis. 2004;10(3):207-214.
5. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. N Engl J Med. 1990;323(18):1228-1233.
6. Eaden J, Abrams K, Mayberry J. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48(4):526-535.
7. Roth M, Petersen G, McElree C, Feldman E, Rotter J. Geographic origins of Jewish patients with inflammatory bowel disease. Gastroenterology. 1989;97(4):900-904.
8. Loftus EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126(6):1504-1517.
9. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5(12):1424-1429.
10. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1785-1794. e1784.
11. Halfvarson J, Bodin L, Tysk C, Lindberg E, Järnerot G. Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics. Gastroenterology. 2003; 124(7):1767-1773.
12. Burger D, Travis S. Conventional medical management of inflammatory bowel disease. Gastroenterology. 2011;140(6):1827-1837.
13. Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol. 2000;95(5): 1263-1276.
14. Harris M, Lichtenstein G. Delivery and efficacy of topical 5-aminosalicylic acid (mesalamine) therapy in the treatment of colitis. Aliment Pharmacol Ther. 2011;33(9):996-1009.
15. Marshall J, Irvine E. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther. 1995;9(3): 293-300.
16. Ford AC, Khan KJ, Achkar J-P, Moayyedi P. Efficacy of oral vs topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2012;107(2): 167-176.
17. Ford AC, Khan KJ, Sandborn WJ, Hanauer SB, Moayyedi P. Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(5): 513-519.
18. Sutherland L, Macdonald J. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;2: CD000543.
19. Sutherland L, Roth D, Beck P, May G, Makiyama K. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;2:CD000544.
20. Ford AC, Achkar JP, Khan KJ, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):601-616.
21. Ito H, Iida M, Matsumoto T, et al. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflamm Bowel Dis. 2010;16(9):1567-1574.
22. Ford AC, Khan KJ, Sandborn WJ, Kane SV, Moayyedi P. Once-daily dosing vs conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(12):2070-2077.
23. Bernard F, Herve H, Gilbert T, et al. Once-daily versus twice-daily mesalazine for active ulcerative colitis: efficacy results from MOTUS, a multicentre, controlled, randomised, investigator-blinded study. Gastroenterology. 2012;142(5 Suppl 1):S-197.
24. Pierik MJ, Flourie B, Hagege H, et al. Once-daily versus twice-daily mesalazine for mild to moderately active ulcerative colitis: mucosal healing and early response data from motus, a multicentre, controlled, randomised, investigator-blinded study. Gastroenterology. 2012;142(5 Suppl 1):S-198.
25. Prantera C, Kohn A, Campieri M, et al. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX® with Asacol®. Aliment Pharmacol Ther. 2009;30(9):908-918.
26. Kane S, Katz S, Jamal MM, et al. Strategies in maintenance for patients receiving long-term therapy (SIMPLE): A study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis. Inflamm Bowel Dis. 2012;18(6):1026-1033.
27. Orchard TR, van der Geest SAP, Travis SPL. Randomised clinical trial: early assessment after 2 weeks of high-dose mesalazine for moderately active ulcerative colitis-new light on a familiar question. Aliment Pharmacol Ther. 2011;33(9):1028-1035.
28. Lichtenstein GR, Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2010;16(2):338-346.
29. Lichtenstein G, Ramsey D, Rubin D. Randomised clinical trial: delayed-release oral mesalazine 4.8g/day vs 2.4g/day in endoscopic mucosal healing-ASCEND I and II combined analysis. Aliment Pharmacol Ther. 2011;33(6):672-678.
30. Sandborn WJ, Hanauer S, Lichtenstein GR, Safdi M, Edeline M, Scott Harris M. Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis-additional results from two controlled studies. Aliment Pharmacol Ther. 2011;34(7):747-756.
31. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130(3):940-987.
32. Carbonnel F. Methotrexate: a drug of the future in ulcerative colitis? Curr Drug Targets. 2011;12(10):1413-1416.
33. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353(23):2462-2476.
34. Yamamoto T, Umegae S, Matsumoto K. Mucosal healing in patients with ulcerative colitis during a course of selective leukocytapheresis therapy: a prospective cohort study. Inflamm Bowel Dis. 2010;16(11):1905-1911.
35. Moss AC, Peppercorn MA. Steroid-refractory severe ulcerative colitis: what are the available treatment options? Drugs. 2008;68(9): 1157-1167.
36. Moscandrew M, Mahadevan U, Kane S. General health maintenance in IBD. Inflamm Bowel Dis. 2009;15(9):1399-1409.
37. Fiorino G, Fries W, De La Rue S, Malesci A, Repici A, Danese S. New drug delivery systems in inflammatory bowel disease: MMX and tailored delivery to the gut. Curr Med Chem. 2010;17(17):1851-1857.
38. Fernandez-Becker NQ, Moss AC. Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes. Drugs. 2008;68(8): 1089-1103.
39. Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007; 132(1):66-75.
40. Hussain F, Ajjan R, Kapur K, Moustafa M, Riley S. Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. Aliment Pharmacol Ther. 2001;15(1):53-62.
41. De Vos M, Verdievel H, Schoonjans R, Praet M, Bogaert M, Barbier F. Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations. Gut. 1992;33(10): 1338-1342.
42. Sandborn W, Hanauer S, Buch A. Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. Aliment Pharmacol Ther. 2004;19(10): 1089-1098.
43. Klotz U. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin Pharmacokinet. 1985;10(4):285-302.
44. Shire US Inc. Lialda (mesalamine) delayed release tablets: US prescribing information [online]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022000s003lbl.pdf. Accessed March 23, 2012.
45. Akiho H, Ihara E, Motomura Y, Nakamura K. Cytokine-induced alterations of gastrointestinal motility in gastrointestinal disorders. World J Gastrointest Pathophysiol. 2011;2(5):72-81.
46. Sandborn W, Balan G, Kuzmak B, Hanauer S. Comparable pharmacokinetics of two delayed release formulations of oral mesalamine. Am J Gastroenterol. 2007;102:S465.
47. Sandborn W, Hanauer S. The pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther. 2003;17(1):29-42.
48. Desreumaux P, Ghosh S. Review article: mode of action and delivery of 5-aminosalicylic acid-new evidence. Aliment Pharmacol Ther. 2006; 24(Suppl 1):2-9.
49. Dubuquoy L, Rousseaux C, Thuru X, et al. PPAR-γ as a new therapeutic target in inflammatory bowel diseases. Gut. September 1, 2006; 55(9):1341-1349.
50. Stenson W, Lobos E. Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils. J Clin Invest. 1982;69(2):494-497.
51. Mahida Y, Lamming C, Gallagher A, Hawthorne A, Hawkey C. 5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease. Gut. 1991;32(1):50-54.
52. Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor [kappa] B activation in mouse colonocytes. Gastroenterology. 1999;116(3):602-609.
53. Egan LJ, Mays DC, Huntoon CJ, et al. Inhibition of interleukin-1-stimulated NF-κB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem. 1999;274(37): 26448-26453.
54. Sandoval M, Liu X, Mannick E, Clark D, Miller M. Peroxynitrite-induced apoptosis in human intestinal epithelial cells is attenuated by mesalamine. Gastroenterology. 1997;113(5):1480-1488.
55. Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once-or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2007;5(1):95-102.
56. Lichtenstein G, Kamm M, Sandborn W, Lyne A, Joseph R. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations. Aliment Pharmacol Ther. 2008;27(11):1094-1102.
57. Sandborn WJ, Kamm MA, Lichtenstein GR, Lyne A, Butler T, Joseph RE. MMX Multi Matrix System® mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther. 2007;26(2):205-215.
58. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflamm Bowel Dis. 2009;15(1):1-8.
59. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomised trial of once-or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut. 2008;57(7):893-902.
60. D'Haens G, Sandborn WJ, Barrett K, et al. Once-daily MMX® mesalamine for endoscopic maintenance of remission of ulcerative colitis. Am J Gastroenterol. May 8, 2012. [Epub ahead of print.]
61. Moss A, Peppercorn M. The risks and the benefits of mesalazine as a treatment for ulcerative colitis. Expert Opin Drug Saf. 2007;6(2):99-107.
62. Gupta MK, Pollack S, Hutchings JJ. Mesalamine induced symptom exacerbation of ulcerative colitis: Case report and brief discussion. World J Gastrointest Pharmacol Ther. 2010;1(6):132-134.
63. Ransford R, Langman M. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut. 2002;51(4): 536-539.
64. Gisbert JP, González-Lama Y, Maté J. 5-Aminosalicylates and renal function in inflammatory bowel disease: A systematic review. Inflamm Bowel Dis. 2007;13(5):629-638.
65. Pitchumoni C, Rubin A, Das K. Pancreatitis in inflammatory bowel diseases. J Clin Gastroenterol. 2010;44(4):246-253.
66. Loftus Jr E, Kane S, Bjorkman D. Short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2004;19(2):179-189.
67. World MJ, Stevens PE, Ashton MA, Rainford DJ. Mesalazine-associated interstitial nephritis. Nephro Dial Transplant. 1996;11(4):614-621.
68. Lowry P, Franklin C, Weaver A, et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut. 2001;49(5):656-664.
69. Marinella M. Mesalamine and warfarin therapy resulting in decreased warfarin effect. Ann Pharmacother. 1998;32(7):841-842.
70. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: A meta-analysis. Reprod Toxicol. 2008;25(2):271-275.
71. Janke KH, Klump B, Gregor M, Meisner C, Haeuser W. Determinants of life satisfaction in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11(3):272-286.
72. Hoivik ML, Moum B, Solberg IC, et al. Health-related quality of life in patients with ulcerative colitis after a 10-year disease course: results from the IBSEN study. Inflamm Bowel Dis. September 20, 2011. [Epub ahead of print.]
73. Solomon D, Yarlas A, Hodgkins P, Karlstadt R, Yen L, Kane S. The impact of MMX mesalazine on disease-specific health-related quality of life in ulcerative colitis patients. Aliment Pharmacol Ther. 2012;35(12):1365-2036.
74. Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001;96(10):2929-2933.
75. Moshkovska T, Stone M, Clatworthy J, et al. An investigation of medication adherence to 5-aminosalicylic acid therapy in patients with ulcerative colitis, using self-report and urinary drug excretion measurements. Aliment Pharmacol Ther. 2009;30(11-12):1118-1127.
76. van Staa TP, Card T, Logan R, Leufkens H. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut. 2005;54(11):1573-1578.
77. Kane S, Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci. 2008;53(4):1020-1024.
78. Higgins PDR, Rubin D, Kaulback K, Schoenfield P, Kane S. Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther. 2009;29(3):247-257.
79. Bernick SJ, Kane S. Insight into the widespread problem of nonadherence to therapy in ulcerative colitis patients. Expert Rev Clin Immunol. 2010;6(4):677-682.
80. Moss ACBK, Ahmed A, Cheifetz AS, Devien J, Yen L. Factors influencing adherence to mesalamine in patients with inflammatory bowel disease: a patient reported qualitative analysis. Am J Gastroenterol. 2011;106(S2):S442.
81. Sandborn WJ, Korzenik J, Lashner B, et al. Once-daily dosing of delayed-release oral mesalamine (400mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology. 2010;138(4):1286-1296.
82. Kane S, Sumner M, Solomon D, Jenkins M. Twelve-month persistency with oral 5-aminosalicylic acid therapy for ulcerative colitis: results from a large pharmacy prescriptions database. Dig Dis Sci. 2011;56(12): 3463-3470.
83. American Hospital Formulary Service Pharmacologic-Therapeutic Classification. 2010. Available from: http://www.ashp.org/ahfs. Accessed May 2012.
84. Brereton N, Bodger K, Kamm MA, Hodgkins P, Yan S, Akehurst R. A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective. J Med Econ. 2010;13(1):148-161.
85. Jess T, Loftus EV, Velayos FS, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Gastroenterology. 2006;130(4):1039-1046.
86. Katsanos KH, Tatsioni A, Pedersen N, et al. Cancer in inflammatory bowel disease 15years after diagnosis in a population-based European collaborative follow-up study. J Crohns Colitis. 2011;5(5):430-442.
87. Jess T, Simonsen J, Jørgensen KT, Pedersen BV, Nielsen NM, Frisch M. Declining risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology. April 19, 2012. [Epub ahead of print.]
88. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2012;10(6):639-645.
89. Tang J, Sharif O, Pai C, Silverman AL. Mesalamine protects against colorectal cancer in inflammatory bowel disease. Dig Dis Sci. 2010;55(6): 1696-1703.
90. Pinczowski D, Ekbom A, Baron J, Yuen J, Adami H. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology. 1994;107(1):117-120.
91. Bernstein CN, Nugent Z, Blanchard JF. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study. Am J Gastroenterol. 2011;106(4):731-736.
92. Terdiman JP, Johnson LK, Kim YS, et al. Chemoprevention of colonic polyps with balsalazide: an exploratory, double-blind, placebo-controlled study. Dig Dis Sci. 2009;54(11):2488-2496.
93. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005;100(6):1345-1353.